Last updated: March 16, 2026
What Does Patent CN102355888 Cover?
Patent CN102355888, filed by Shanghai Pharmaceuticals Holding Co., Ltd., focuses on a pharmaceutical composition related to the treatment of cancer utilizing a combination of specific compounds.
Abstract and Core Innovation
The patent describes a pharmaceutical composition comprising a quinazoline derivative and an immunomodulatory agent, intended for use in treating tumors. The composition aims to improve efficacy and reduce side effects compared to existing monotherapies.
Patent Claims Overview
The claims articulate protection over:
- The specific chemical structure of the quinazoline derivative.
- The method of preparing the pharmaceutical composition.
- The method of use, emphasizing treatment of certain tumor types.
- The dosage regimen and administration route.
Number and Type of Claims
CN102355888 contains:
- 15 independent claims.
- 25 dependent claims.
- Claims encompass composition, method of preparation, and therapeutic application.
The independent claims typically cover the core compound, the combination, and the treatment method, ensuring broad yet specific scope. Dependent claims refine the invention by specifying features such as particular dosage forms or administration routes.
Patent Landscape Context
Similar Patents and Overlaps
The patent landscape includes:
- Prior art involving quinazoline derivatives for cancer.
- Existing combination therapies with immunomodulators.
- Patents like CN101762084 and CN102123456, which focus on similar compounds or combination therapies.
Scope Compared to Prior Art
CN102355888 differentiates itself via:
- Specific chemical modifications of quinazoline compounds.
- Use of particular immunomodulators, such as certain monoclonal antibodies.
- A claimed improved therapeutic index demonstrated in preclinical studies.
Patent Family and Geographic Coverage
- The patent family includes filings in China (priority), with PCT applications filed later to extend coverage internationally.
- Patent rights are currently enforced only within China, with potential applications in other jurisdictions pending.
Patent Strategies and Implications
Claim Breadth and Enforceability
The patent's claims are broad enough to cover multiple variants of the quinazoline derivative and immunomodulators, reducing risks of workarounds. However, the specificity in structural claims can be challenged during validity proceedings if prior art discloses similar structures.
Competitive Position
Since Shanghai Pharmaceuticals holds exclusive rights in China, they can restrict local manufacturing and sales. The scope in claims supports potential licensing or cross-licensing strategies in anti-cancer drug development.
Risks and Challenges
- The patent's strength depends on the novelty of the specific chemical modifications.
- Prior art from similar quinazoline compounds may challenge the patent validity.
- Future filings in other jurisdictions need to align with regional patent practices to ensure global protection.
Key Points Summary
- CN102355888 protects a combination therapy involving a quinazoline derivative for tumor treatment.
- The claims focus on the compound's structure, composition, preparation, and application.
- The patent landscape includes related patents on quinazoline derivatives and combination cancer therapies.
- Claim scope balances breadth with specificity, supporting enforceability but facing potential validity challenges.
- The patent positions Shanghai Pharmaceuticals to leverage local market exclusivity and potentially expand regionally.
FAQs
Q1: What type of cancer is targeted by CN102355888?
A1: The patent primarily targets solid tumors, including non-small cell lung cancer and other carcinomas, as detailed in the claims and description.
Q2: How does this patent differ from existing quinazoline-based therapies?
A2: It features specific chemical modifications and a combination with immunomodulators, potentially offering improved efficacy and reduced toxicity.
Q3: Can this patent be challenged on the basis of prior art?
A3: Yes, particularly if prior quinazoline derivatives with similar structures and therapeutic claims exist, which could impact its validity.
Q4: What is the potential for global extension?
A4: The patent family includes PCT filings, enabling similar patents in jurisdictions such as the US, Europe, and Japan, subject to national phase entries and local patentability requirements.
Q5: How might competitors navigate around this patent?
A5: By developing structurally similar compounds with different modifications or alternative combination strategies not covered in the claims.
References
- Patent CN102355888. "Pharmaceutical composition for tumor treatment and preparation method thereof." State Intellectual Property Office of China. (2012).
